Guggenheim analyst Charles Zhu downgraded MacroGenics to Neutral from Buy without a price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MGNX:
- MacroGenics Provides Corporate Update and 2022 Financial Results
- MacroGenics expands license agreement with Synaffix
- MacroGenics informs investors of no exposure to Silicon Valley Bank
- MacroGenics price target raised to $17 from $15 at Stifel
- MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million